A Phase 1 Study of AUTX-703 in People With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Full Title

A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Purpose

Researchers want to find the best dose of AUTX-703 to give safely in people with blood cancers. The people in this study have acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Their disease came back or keeps getting worse after treatment.

AUTX-703 breaks down and removes proteins called KAT2A and KAT2B, which are involved in the normal development of cells. The KAT2A and KAT2B proteins can be overactive in certain types of cancers, such as AML and MDS. This allows cancer cells to remain in a cancerous state and grow, rather than develop into normal cells.

AUTX-703 pushes cancer cells to develop into normal cells and causes cancer to stop growing and spreading. It is taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Xin Wang at 646-608-4365.